NCT02118831View on ClinicalTrials.gov

Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

April 30, 2014

Conditions
Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Interventions
BIOLOGICAL

Blood Sample Collection

Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.

DRUG

Aflibercept

an intravitreal injection of Aflibercept administered three times on a monthly basis.

DRUG

Bevacizumab

an intravitreal injection of Bevacizumab administered three times on a monthly basis.

DRUG

Ranibizumab

an intravitreal injection of Ranibizumab administered three times on a monthly basis.

All Listed Sponsors
lead

California Retina Consultants

OTHER

NCT02118831 - Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF | Biotech Hunter | Biotech Hunter